Ve800
Clinical Trials Overview
1 trials found
About Ve800
Ve800 is an investigational medication currently being studied in clinical trials for certain types of advanced or metastatic cancer, including microsatellite-stable (MSS) colorectal cancer (CRC). It is being tested in combination with nivolumab, an immunotherapy drug already approved for other cancers. The goal of the trials is to see if this combination is safe and effective in patients whose tumors may not respond well to other treatments. Ve800 is designed to potentially boost the body's immune system to fight the cancer. It is not yet approved for use in CRC or any other cancer.
Category
Other Medications
Mechanism
Ve800 is designed to enhance the immune response against the tumor. It is being studied in combination with nivolumab, which is an immunotherapy drug that works by blocking a protein (PD-1) that prevents the immune system from attacking cancer cells. The specific way Ve800 enhances the immune response is being investigated in clinical trials.
1
Total Trials
0
Recruiting
0
Active
1
Completed
56
Total Enrollment
1
Countries
NCT04208958
Phase 1
Completed
56 patients
Medications:
Nivolumab
VE800
This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer
United States